Evidence map›Paper›PMID 32691991›Full record

ArticleCancer medicine2020

Puerarin 6″-O-xyloside suppressed HCC via regulating proliferation, stemness, and apoptosis with inhibited PI3K/AKT/mTOR.

Long Li, Jun-Dong Liu, Guo-Dong Gao, Kai Zhang, Yu-Wei Song, Hong-Bo Li

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Long LiDepartment of General Surgery, People's Hospital of Rizhao, Rizhao, Shandong Province, China.
Jun-Dong LiuDepartment of General Surgery, People's Hospital of Rizhao, Rizhao, Shandong Province, China.
Guo-Dong GaoDepartment of General Surgery, People's Hospital of Rizhao, Rizhao, Shandong Province, China.
Kai ZhangDepartment of General Surgery, People's Hospital of Rizhao, Rizhao, Shandong Province, China.
Yu-Wei SongDepartment of General Surgery, People's Hospital of Rizhao, Rizhao, Shandong Province, China.
Hong-Bo LiDepartment of General Surgery, People's Hospital of Rizhao, Rizhao, Shandong Province, China.ORCID 0000-0002-3206-2375
People’s Hospital of Rizhao · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Puerarin 6″-O-xyloside is a tumor suppressive derivate of Puerarin that is recently characterized as a lysine-specific demethylase 6B inhibitor. Here we investigated the effects of Puerarin 6″-O-xyloside in hepatocellular carcinoma (HCC) cell lines SMMC-7721 and HepG2. Cell viability, proliferation, stemness, protein expression, and autophagy were tested by CCK-8, colony formation, sphere formation, western blotting, and LC3B GFP puncta per cell, respectively. Apoptosis, CD133-positive cells, and JC-1-labeled mitochondrial membrane potential were measured by flow cytometry. The effects of Puerarin 6″-O-xyloside in vivo were explored in HepG2 xenograft mice. Puerarin 6″-O-xyloside inhibited cell viability, proliferation, and stemness, and promoted apoptosis in both SMMC-7721 and HepG2 cells. Further experiments showed promoted autophagy and decreased mitochondrial membrane potential, and decreased expression of p-PI3K, p-AKT, and p-mTOR in HepG2 cells. Co-administration of 3-MA with Puerarin 6″-O-xyloside obviously augmented these effects including inhibited protein expression of p-PI3K, p-AKT, and p-mTOR, and inhibited proliferation, promoted apoptosis, and decreased stemness. In HepG2 xenograft mice, 100 mg/kg/d Puerarin 6″-O-xyloside significantly suppressed tumor growth, stemness, and apoptosis. In conclusion, our study indicated that Puerarin 6″-O-xyloside decreased cell viability, proliferation, and stemness, and promoted autophagy and mitochondria-dependent apoptosis of HCC, at least partly through inhibiting PI3K/AKT/mTOR. These results highlighted Puerarin 6″-O-xyloside as a promising prodrug that could inhibit both PI3K/AKT/mTOR and epigenetic demethylation.

Indexed as

AC133 AntigenAdenineAnimalsApoptosisAutophagyCarcinoma, HepatocellularCell Line, TumorCell ProliferationDisease ProgressionGlycosidesHep G2 CellsHumansIsoflavonesLiver NeoplasmsMaleMembrane Potential, Mitochondrial3-methyladenineAC133 AntigenAdenineGlycosidesIsoflavonesMTOR protein, humanNeoplasm ProteinsPhosphatidylinositol 3-KinasesPROM1 protein, humanProto-Oncogene Proteins c-aktpuerarin 6'-O-xylosideTOR Serine-Threonine KinasesKDM6Bliver cancermTORPI3KPuerarin 6″-O-xyloside

Identifiers

PMID32691991
PMCPMC7476825
OpenAlexW3043901294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.